{"url_path":"/sec/ntla/8-k/2026-06-15/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1652130/0001193125-26-270358-index.html","accession_number":"0001193125-26-270358","cik":"0001652130","ticker":"NTLA","issuer_name":"Intellia Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1652130/0001193125-26-270358-index.html","primary_entity_key":"0001652130","primary_entity_name":"Intellia Therapeutics, Inc."},"word_count":144,"has_tables":true,"body_markdown":"## Item 7.01 Regulation FD Disclosure.\n\nOn June 13, 2026, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) issued a press release titled “Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\nThe information under this Item 7.01, including Exhibit 99.1 hereto, is being furnished herewith and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing."}